Gianfranco Delle Fave

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10644647/publications.pdf

Version: 2024-02-01

88 papers	8,082 citations	70961 41 h-index	51492 86 g-index
88 all docs	88 docs citations	88 times ranked	7750 citing authors

#	Article	IF	Citations
1	Gastroenteropancreatic neuroendocrine tumours. Lancet Oncology, The, 2008, 9, 61-72.	5.1	1,474
2	Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet, The, 2016, 387, 968-977.	6.3	962
3	Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway. Journal of Clinical Oncology, 2010, 28, 245-255.	0.8	497
4	Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Modern Pathology, 2010, 23, 824-833.	2.9	396
5	Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocrine-Related Cancer, 2005, 12, 1083-1092.	1.6	360
6	ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms. Neuroendocrinology, 2012, 95, 74-87.	1.2	294
7	Thyroxine in Goiter,Helicobacter pyloriInfection, and Chronic Gastritis. New England Journal of Medicine, 2006, 354, 1787-1795.	13.9	284
8	Metastatic and Locally Advanced Pancreatic Endocrine Carcinomas: Analysis of Factors Associated With Disease Progression. Journal of Clinical Oncology, 2011, 29, 2372-2377.	0.8	261
9	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers. Neuroendocrinology, 2009, 90, 194-202.	1.2	226
10	Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study. Gastrointestinal Endoscopy, 2012, 76, 570-577.	0.5	158
11	Well-Differentiated Gastric Tumors/Carcinomas. Neuroendocrinology, 2006, 84, 158-164.	1.2	133
12	Clinicopathological Features of Pancreatic Endocrine Tumors: A Prospective Multicenter Study in Italy of 297 Sporadic Cases. American Journal of Gastroenterology, 2010, 105, 1421-1429.	0.2	125
13	Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. European Journal of Gastroenterology and Hepatology, 2001, 13, 1449-1456.	0.8	106
14	Role of Resection of the Primary Pancreatic Neuroendocrine Tumour Only in Patients with Unresectable Metastatic Liver Disease: A Systematic Review. Neuroendocrinology, 2011, 93, 223-229.	1.2	103
15	Occurrence and Risk Factors for Autoimmune Thyroid Disease in Patients with Atrophic Body Gastritis. American Journal of Medicine, 2008, 121, 136-141.	0.6	91
16	Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors. Oncologist, 2014, 19, 966-974.	1.9	84
17	Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches. Clinical Cancer Research, 2013, 19, 2842-2849.	3.2	80
18	Quantitative ultrastructure of endocrine cells of oxyntic mucosa in Zollinger-Ellison syndrome. Gastroenterology, 1990, 99, 17-26.	0.6	79

#	Article	IF	Citations
19	Risk of pancreatic malignancy and mortality in branch-duct IPMNs undergoing surveillance: A systematic review and meta-analysis. Digestive and Liver Disease, 2016, 48, 473-479.	0.4	78
20	Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1411-1422.	5.1	74
21	Endocrine tumours of the stomach. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2005, 19, 659-673.	1.0	72
22	Everolimus in advanced, progressive, wellâ€differentiated, nonâ€functional neuroendocrine tumors: <scp>RADIANT</scp>â€4 lung subgroup analysis. Cancer Science, 2018, 109, 174-181.	1.7	72
23	Molecular pathology and genetics of pancreatic endocrine tumours. Journal of Molecular Endocrinology, 2012, 49, R37-R50.	1.1	70
24	Exocrine Pancreatic Insufficiency in Diabetic Patients: Prevalence, Mechanisms, and Treatment. International Journal of Endocrinology, 2015, 2015, 1-7.	0.6	68
25	Active Surveillance Beyond 5 Years Is Required for Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms Undergoing Non-Operative Management. American Journal of Gastroenterology, 2017, 112, 1153-1161.	0.2	66
26	Gastric and duodenal neuroendocrine tumours. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 719-735.	1.0	62
27	Early onset pancreatic cancer: Risk factors, presentation and outcome. Pancreatology, 2015, 15, 151-155.	0.5	60
28	Sarcopenia Predicts Reduced Survival in Patients with Hepatocellular Carcinoma at First Diagnosis. Annals of Hepatology, 2017, 16, 107-114.	0.6	59
29	Diagnosis and Management of Pernicious Anemia. Current Gastroenterology Reports, 2011, 13, 518-524.	1.1	57
30	<scp>TERT</scp> gene harbors multiple variants associated with pancreatic cancer susceptibility. International Journal of Cancer, 2015, 137, 2175-2183.	2.3	57
31	Risk Factors for Disease Progression in Advanced Jejunoileal Neuroendocrine Tumors. Neuroendocrinology, 2012, 96, 32-40.	1.2	55
32	The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients. International Journal of Molecular Sciences, 2017, 18, 730.	1.8	55
33	Promising Advances in the Treatment of Malignant Pancreatic Endocrine Tumors. New England Journal of Medicine, 2011, 364, 564-565.	13.9	53
34	Everolimus in Pancreatic Neuroendocrine Carcinomas G3. Pancreas, 2017, 46, 302-305.	0.5	53
35	Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells. Endocrine-Related Cancer, 2007, 14, 111-124.	1.6	52
36	Risk Factors for Sporadic Pancreatic Endocrine Tumors. American Journal of Gastroenterology, 2009, 104, 3034-3041.	0.2	52

#	Article	IF	Citations
37	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1197-1205.	3.3	50
38	Advanced Digestive Neuroendocrine Tumors. Pancreas, 2014, 43, 212-218.	0.5	46
39	Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms. PLoS ONE, 2017, 12, e0179445.	1.1	45
40	Vitamins D and K as Factors Associated with Osteopathy in Chronic Pancreatitis: A Prospective Multicentre Study (P-BONE Study). Clinical and Translational Gastroenterology, 2018, 9, e197.	1.3	44
41	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix. Annals of Surgery, 2020, 271, 527-533.	2.1	44
42	Endoscopy-guided ablation of pancreatic lesions: Technical possibilities and clinical outlook. World Journal of Gastrointestinal Endoscopy, 2017, 9, 41.	0.4	44
43	Mucosal adhesion and anti-inflammatory effects ofLactobacillus rhamnosusGG in the human colonic mucosa: A proof-of-concept study. World Journal of Gastroenterology, 2018, 24, 4652-4662.	1.4	43
44	Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome. Oncologist, 2017, 22, 409-415.	1.9	42
45	Gastric Neuroendocrine Tumors. Neuroendocrinology, 2004, 80, 16-19.	1.2	41
46	Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Oncotarget, 2016, 7, 57011-57020.	0.8	41
47	Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition. Oncotarget, 2014, 5, 5381-5391.	0.8	41
48	White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths. Digestive and Liver Disease, 2014, 46, 579-589.	0.4	40
49	Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. Scientific Reports, 2017, 7, 13024.	1.6	39
50	Clinical Usefulness of 18 Fâ€Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Enteroâ€Pancreatic Neuroendocrine Neoplasms. Oncologist, 2018, 23, 186-192.	1.9	39
51	Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. Annals of Surgical Oncology, 2018, 25, 3200-3206.	0.7	39
52	Molecular target therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical perspectives. Critical Reviews in Oncology/Hematology, 2009, 72, 110-124.	2.0	36
53	Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. Cancer Treatment Reviews, 2010, 36, S87-S94.	3.4	36
54	Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. International Journal of Cancer, 2019, 144, 1275-1283.	2.3	36

#	Article	IF	Citations
55	Sampling Strategies for Analysis of Enterochromaffin-like Cell Changes in Zollinger-Ellison Syndrome. American Journal of Clinical Pathology, 2000, 114, 419-425.	0.4	34
56	Src kinase activity coordinates cell adhesion and spreading with activation of mammalian target of rapamycin in pancreatic endocrine tumour cells. Endocrine-Related Cancer, 2011, 18, 541-554.	1.6	32
57	Risk and protective factors for the occurrence of sporadic pancreatic endocrine neoplasms. Endocrine-Related Cancer, 2017, 24, 405-414.	1.6	30
58	Alternative polyadenylation of ZEB1 promotes its translation during genotoxic stress in pancreatic cancer cells. Cell Death and Disease, 2017, 8, e3168-e3168.	2.7	30
59	Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals. World Journal of Gastrointestinal Endoscopy, 2015, 7, 833.	0.4	28
60	Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study. Neuroendocrinology, 2016, 103, 531-537.	1.2	28
61	Gut microbiota and pancreatic diseases. Minerva Gastroenterology, 2017, 63, 399-410.	0.3	26
62	Prevalence of chronic pancreatitis: Results of a primary care physician-based population study. Digestive and Liver Disease, 2017, 49, 535-539.	0.4	25
63	Diagnostic and therapeutic role of endoscopy in gastroenteropancreatic neuroendocrine neoplasms. Digestive and Liver Disease, 2014, 46, 9-17.	0.4	22
64	Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 594-601.	1.4	20
65	Endoscopic scores for inflammatory bowel disease in the era of â€˜mucosal healingâ€™: Old problem, new perspectives. Digestive and Liver Disease, 2016, 48, 703-708.	0.4	20
66	Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Oncotarget, 2017, 8, 46624-46634.	0.8	20
67	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. Pancreatology, 2018, 18, 198-203.	0.5	18
68	Hepatitis B in patients with hematological diseases: An update. World Journal of Hepatology, 2017, 9, 1043.	0.8	17
69	Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. Hpb, 2013, 15, 935-943.	0.1	16
70	Recurrent biliary acute pancreatitis is frequent in a real-world setting. Digestive and Liver Disease, 2018, 50, 277-282.	0.4	16
71	Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumors. Scientific Reports, 2016, 6, 39565.	1.6	15
72	SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Scientific Reports, 2017, 7, 43812.	1.6	15

#	Article	IF	Citations
73	Comparison of diffusion-weighted imaging and gadoxetic acid-enhanced MR images in the evaluation of hepatocellular carcinoma and hypovascular hepatocellular nodules. Clinical Imaging, 2015, 39, 468-475.	0.8	14
74	Digestive neuroendocrine neoplasms: A 2016 overview. Digestive and Liver Disease, 2016, 48, 829-835.	0.4	14
75	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. Cancer Medicine, 2017, 6, 1493-1499.	1.3	11
76	Signalling Pathways Passing Src in Pancreatic Endocrine Tumours: Relevance for Possible Combined Targeted Therapies. Neuroendocrinology, 2013, 97, 67-73.	1.2	10
77	Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death. Oncology Reports, 2018, 39, 1984-1990.	1.2	10
78	The prevalence of pancreatic cystic lesions in patients with liver cirrhosis is double that in controls. United European Gastroenterology Journal, 2017, 5, 1007-1014.	1.6	8
79	Novel Molecular Targets for the Treatment of Gastroenteropancreatic Endocrine Tumors: Answers and Unsolved Problems. International Journal of Molecular Sciences, 2013, 14, 30-45.	1.8	7
80	Critical Review of the Evidence on 5-Aminosalicilate for Chemoprevention of Colorectal Cancer in Ulcerative Colitis: A Methodological Question. Current Clinical Pharmacology, 2014, 9, 84-90.	0.2	7
81	â€œMucosal healingâ€•in ulcerative colitis: Between clinical evidence and market suggestion. World Journal of Gastrointestinal Pathophysiology, 2014, 5, 54.	0.5	7
82	Inhibitory effect of somatostatin on neutral amino acid transport in isolated brain microvessels. Journal of Neurochemistry, 2001, 78, 349-357.	2.1	2
83	Risk for Colorectal Adenomas Among Patients with Pancreatic Intraductal Papillary Mucinous Neoplasms: a Prospective Case- Control Study. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 445-450.	0.5	2
84	Searching for biomarkers in clinical practice: the prevalence and clinical significance of hypergammaglobulinemia in inflammatory bowel disease patients. Journal of Gastrointestinal and Liver Diseases, 2020, 25, 565-568.	0.5	2
85	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al.. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 176-177.	3.3	1
86	Statin Use and Survival in Resectable Pancreatic Cancer: Confounders and Mechanisms. American Journal of Gastroenterology, 2016, 111, 436.	0.2	1
87	A Critical View of Molecularly Target Therapy for Digestive Endocrine Tumours. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2007, 1, 119-126.	0.7	0
88	Therapy for Locoregional Disease: Stomach/Duodenum, Colon/Rectum. , 2018, , 219-234.		0